that atherosclerosis progression, including plaque instability, is associated with chronic inflammation in the vessel wall is receiving much attention as a risk factor for major CHD events. [7] [8] [9] Thus, to develop effective preventive and therapeutic approaches, it is necessary to identify molecular mechanisms underlying chronic inflammatory activity that may accelerate atherosclerosis progression.
We recently found that angiopoietin-like protein 2 (Angptl2) plays important pathological roles in various noninfectious inflammatory diseases, such as obesity-related insulin resistance, 10 rheumatoid arthritis, 11 and chemically induced cancer. 12 Here, we report that Angptl2 protein levels in aorta tissue from the apolipoprotein E (ApoE −/− ) knockout mouse are positively correlated with atherosclerosis severity. Histological analysis demonstrated abundant Angptl2 expression in atheromatous plaques of patients with CHD, particularly in endothelial cells and infiltrated macrophages. Angptl2 deficiency in ApoE −/− (ApoE −/− /Angptl2 −/− ) mice attenuated atherosclerosis severity by decreasing vascular inflammation through decreasing the number of macrophages infiltrating atheromatous plaques. Interestingly, the severity of phenotypes seen in ApoE −/− /Angptl2 −/− recipient mice transplanted with ApoE −/− /Angptl2 +/+ bone marrow (BM) cells was also significantly reduced compared with ApoE −/− /Angptl2 +/+ recipients transplanted with ApoE −/− /Angptl2 +/+ BM cells, indicating that deficiency of non-BM cell-derived Angptl2 in ApoE −/− mice contributes to decreased atherosclerosis severity. Conversely, ApoE −/− mice crossed with transgenic mice expressing Angptl2 driven by the Tie2 promoter (ApoE −/− /Tie2-Angptl2 Tg), which show increased Angptl2 expression in endothelial cells but not in differentiated hematopoietic lineage cells including monocytes/macrophages, exhibited more severe atherosclerosis and increased vascular inflammation. In addition, Angptl2 activated proinflammatory nuclear factor (NF)-κB signaling in endothelial cells in vitro and increased monocyte/macrophage chemotaxis. Transgenic mice expressing Angptl2 driven by the Tie2 promoter (Tie2-Angptl2 Tg) mice alone did not develop atheromatous plaques but did show endothelium-dependent vasodilatory dysfunction (hereafter designated endothelial dysfunction), likely because of decreased production of endothelial cell-derived nitric oxide (NO). Conversely, in mice, Angptl2 deficiency decreased endothelial dysfunction induced by obesity. Overall, our findings indicate that endothelial cellderived Angptl2 accelerates vascular inflammation, leading to endothelial dysfunction and atherosclerosis development.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Circulating Angptl2 Concentrations and Angptl2 Expression Levels in Vascular Tissue Positively Correlate With Atherosclerosis Severity in Mice
Circulating Angptl2 concentrations markedly increase with age in ApoE −/− mice, which exhibit atherosclerosis development ( Figure 1A ). Circulating Angptl2 concentrations in wild-type mice exhibiting little evidence of atherosclerosis in the aorta also increase with age, but to a lesser degree ( Figure 1A ). We observed that both the severity of atherosclerosis and the expression of Angptl2 protein levels in aortic vessels increased as ApoE −/− mice aged ( Figure 1B and 1C) . Increased serum levels of cholesterol, triglycerides, free fatty acids (FFAs), and homeostasis model assessment-insulin resistance were not exacerbated with age in ApoE −/− mice ( Table  I in the online-only Data Supplement). Overall, these observations suggest that, despite the fact that aging mice exhibit baseline increases in circulating Angptl2 levels, the presence of atherosclerosis exacerbates those increases, suggesting that cells in an atherosclerotic lesion may secrete Angptl2. These findings also suggest that circulating Angptl2 levels reflect atherosclerosis severity, not dyslipidemia.
Angptl2 Is Abundantly Expressed in Endothelial Cells and Macrophages Infiltrating Atherosclerotic Vessels of Patients With CHD
Patients with CHD showed significantly increased levels of circulating Angptl2 compared with age-matched control subjects ( Figure 2A ; Table II in the online-only Data Supplement). Immunohistochemical analysis of serial sections of coronary arteries collected at autopsy from 10 patients with CHD indicated abundant Angptl2 expression in vascular endothelial cells (VECs) and in macrophages infiltrating plaque sites, and also in VECs at sites of nonatherosclerotic plaques ( Figure 2B ; Figure IA and IB in the online-only Data Supplement). To determine which cells express Angptl2, we undertook double-immunofluorescence staining of human coronary artery tissue using antibodies against Angptl2 and cluster of differentiation (CD)-31 (a marker of endothelial cells and some hematopoietic lineage/immune cells) or CD68 (a macrophage marker) by confocal microscopy. Both CD31 + cells and CD68 + cells coexpressed Angptl2 ( Figure 2C and 2D), indicating that Angptl2 is expressed in both VECs and infiltrated macrophages in atheromatous plaque lesions in human tissues. 
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Angptl2 Deficiency Decreases Inflammation in Atherosclerotic Vascular Tissue and Attenuates Atherosclerosis Progression in ApoE −/− Mice
We next asked whether Angptl2 derived from endothelial cells and macrophages in atherosclerotic vascular tissue contributes to atherosclerosis development. Real-time polymerase chain reaction (RT-PCR) analysis of BM cells from wild-type mice revealed abundant Angptl2 expression in CD45 -Ter119 − CD31 + and CD45 − Ter119 − VE-cad + VECs and Gr-1 + monocyte/macrophages, respectively ( Figure VIIIC in the online-only Data Supplement). Thus, we used a double-knockout strategy by crossing ApoE −/− with Angptl2 −/− mice to assess effects of Angptl2 −/− loss in atherosclerotic mice. The average size of atherosclerotic lesions seen in double-knockout mice was significantly smaller than lesions exhibited by ApoE −/− /Angptl2 +/+ single-knockout littermates, when mice were assessed at 32 weeks ( Figure 3A ). To ascertain whether Angptl2 deficiency altered plaque vulnerability to rupture, we assessed brachiocephalic tissue sections using hematoxylin and eosin, Elastica van Gieson, and Masson trichrome staining. We characterized the hematoxylin and eosin-negative acellular area, which is indicative of the necrotic core, primarily by cholesterol crystal accumulation ( Figure 3B ), as described elsewhere. 13, 14 Fibrous cap thickness was assessed by staining using Masson trichrome ( Figure 3C ) and α-smooth muscle actin antibodies (data not shown). 13, 14 Angptl2 deficiency significantly decreased the lesion area and the ratio of the necrotic core area to the total lesion area but increased fibrous cap thickness ( Figure 3B and 3C). Immunohistochemistry with an anti-CD68 antibody revealed that the number of infiltrated macrophages in a plaque significantly decreased in ApoE −/− /Angptl2 −/− mice relative to ApoE −/− littermates ( Figure 3D ). In vitro transmigration assays using the human monocyte line THP-1 revealed that Angptl2 increased chemotactic activity of monocytes/ macrophages ( Figure , suggesting that Angptl2 deficiency partially shifts the macrophage spectrum toward an anti-inflammatory state. We conclude that Angptl2 deficiency antagonizes vascular inflammation by decreasing macrophage infiltration of atherosclerotic plaques and partially shifting the macrophage spectrum toward an anti-inflammatory population. As shown in Figures 1 and 2 , endothelial cells and macrophages are the primary cells that secrete Angptl2 in atherosclerotic lesions. Thus, we asked whether Angptl2 derived from non-BM cells, such as endothelial cells, contributed to Overall, these observations strongly suggest that Angptl2 deficiency slows atherosclerosis progression and decreases phenotypes associated with plaque instability in ApoE −/− mice.
Endothelial Cell-Derived Angptl2 Accelerates Atherosclerosis Progression in ApoE −/− Mice
We next asked whether increased endothelial cell-derived Angptl2 contributes to atherosclerosis progression by Tie2-Angptl2 Tg mice ( Figure VIIIA in the online-only Data Supplement). RT-PCR analysis of BM cells from wild-type mice revealed abundant Tie2 expression in VECs and LSK (lineage marker-negative, Sca-1 + , c-Kit + ) hematopoietic stem cells, and little Tie2 expression in other differentiated hematopoietic lineage cells including monocytes/macrophages ( Figure VIIIB in the online-only Data Supplement). In addition, we observed that significant increases in Angptl2 expression in Tie2-Angptl2 Tg relative to wild-type control mice were restricted to endothelial cells and hematopoietic stem cells and did not occur in other cell types ( Figure VIIIC in online-only Data Supplement). After analysis of 7 independent Tie2-Angptl2 Tg lines, we observed abundant Angptl2 mRNA levels relative to wild-type mice in vessels that had been separated from perivascular adipose tissue ( Figure  VIIID in the online-only Data Supplement). The lines also showed equivalent Angptl2 protein levels in vessel tissues ( Figure VIIIE and VIIIF in the online-only Data Supplement). Angptl2 mRNA levels in cultured primary endothelial cells isolated from Tie2-Angptl2 Tg mice were 2-to 3-fold higher than those from non-Tg controls ( Figure VIIIG in the online-only Data Supplement). We then crossed ApoE −/− with Tie2-Angptl2 Tg mice to construct ApoE −/− /Tie2-Angptl2 Tg mice. We observed that the average lesion size in ApoE −/− / Tie2-Angptl2 Tg mice was significantly larger than lesions seen in ApoE −/− mice ( Figure 4A ). Furthermore, ApoE −/− / Tie2-Angptl2 Tg mice exhibited an increased lesion area and a larger ratio of necrotic core to total lesion area ratio along with decreased thickness of the fibrous cap ( Figure 4B and 4C). Unlike phenotypes observed in ApoE −/− /Angptl2 −/− mice, the number of CD68-positive macrophages in the lesion area significantly increased in ApoE −/− /Tie2-Angptl2 Tg mice relative to ApoE −/− littermates ( Figure 4D ). RT-PCR analysis of vascular tissues revealed increased expression of markers indicative of vascular inflammation, general inflammation, and macrophage accumulation in ApoE −/− /Tie2-Angptl2 Tg mice compared with ApoE −/− littermates ( Figure 4E ). ApoE −/− /Tie2-Angptl2 Tg mice showed decreased expression of the antiinflammatory markers arginase-1 and Ym1 and comparable expression of Fizz1 and Mgl1 in vascular tissue ( Figure IXA in the online-only Data Supplement). Tg and control mice also showed equivalent levels of CD11c and integrin β chain 2 (Itgβ2) in vascular tissue ( Figure IXB in the online-only Data Supplement). To further examine whether macrophage inflammatory phenotypes were altered in ApoE −/− /Tie2-Angptl2 Tg mice, we examined expression of M1 and M2 markers in thioglycollate-induced peritoneal macrophages from Tg and control mice. We observed no difference in the expression of proinflammatory markers, such as TNF-α, IL-6, IL-1β, and inducible NO synthase between the 2 groups ( Figure XA in the online-only Data Supplement). After IL-4 treatment of thioglycollate-induced peritoneal macrophages, we observed no difference in expression levels of the anti-inflammatory markers arginase-1, Fizz1, and Mgl1 between the 2 groups, whereas Ym1 expression level in ApoE −/− /Tie2-Angptl2 Tg mice was increased compared with ApoE −/− littermates ( Figure  XB in the online-only Data Supplement). We also observed no differences in serum levels of cholesterol, triglycerides, and FFAs homeostasis model assessment-insulin resistance, systolic blood pressure, or leukocyte numbers between the 2 groups ( Figure XI in the online-only Data Supplement). Overall, these findings suggest that in ApoE −/− /Tie2-Angptl2 Tg mice, atherosclerosis progression, including plaque instability, is primarily because of Angptl2-induced vascular inflammation likely promoted by increased numbers of infiltrated macrophages in atherosclerotic plaques, and that this activity is independent of insulin resistance, dyslipidemia, and the number of circulating leukocytes.
Angptl2 Exacerbates Proinflammatory Signaling by Activating the Integrin α5β1/NF-κB Pathway in Coronary Endothelial Cells
We previously reported that Angptl2 acts by binding the integrin α5β1 receptor on various cell types. 10, 11, 15 Others recently demonstrated that Angptl2 maintains stemness of hematopoietic stem cells and supports leukemia development by binding the leukocyte immunoglobulin-like receptor B2 (LILRB2) or LILRB3. 16 Our RT-PCR analysis revealed minimal expression of LILRB2 or LILRB3 in human coronary artery endothelial cells (HCAECs), whereas both were abundantly expressed in positive control human acute (HL-60) leukemia cells ( Figure XII in the online-only Data Supplement).
Fluorescence-activated cell sorting analysis confirmed that HCAECs express neither LILRB2 nor LILRB3 but rather show robust expression of integrins α5β1 and αVβ3 ( Figure  XIIIA and XIIIB in the online-only Data Supplement). Western analysis of HCAECs revealed increased IκB degradation after stimulation with recombinant human Angptl2 protein, an activity blocked by treatment with an integrin α5β1-neutralizing antibody but not by isotype-matched IgG control or with integrin αVβ3-neutralizing antibody ( Figure XIVA in the onlineonly Data Supplement). Immunocytochemistry revealed that nuclear translocation of the NF-κB subunit p65 increased in HCAECs stimulated with recombinant human Angptl2 protein, an activity also suppressed treatment with an integrin α5β1-neutralizing antibody but not with isotype-matched IgG control or integrin αVβ3-neutralizing antibody ( Figure  XIVB 
Endothelial Cell-Derived Angptl2 Promotes Endothelial Dysfunction in Nonobese and Nondyslipidemic Wild-Type Mice
Tie2-Angptl2 Tg mice showed little evidence of atheromatous plaque formation in the aorta, even at an advanced age ( Figure 5A ), suggesting that Angptl2 alone has little effect on plaque development. Endothelium-derived NO antagonizes atherosclerosis by suppressing vascular inflammation 17, 18 and acting as a vasodilator to relax vascular smooth muscle cells. 19 Chronic inflammation in VECs decreases NO production, 20 promoting atherosclerosis progression 21 and endotheliumdependent vasodilatory dysfunction, an early indicator of atherosclerosis. [22] [23] [24] Therefore, we asked whether endothelial cell-derived Angptl2 altered NO release in Tie2-Angptl2 Tg mice expressing abundant Angptl2 protein levels in endothelial cells ( Figure 5B ). To do so, we assessed endothelium-dependent relaxation in response to acetylcholine administration, which induces NO release from endothelial cells. 25, 26 Initially, we observed no change in vascular contractile reactivity stimulated by phenylephrine treatment in Tie2-Angptl2 Tg or wild-type mice (data not shown). By contrast, after vascular contraction, endothelium-dependent relaxation in response to acetylcholine was impaired in Tie2-Angptl2 Tg compared with wild-type mice (Figure 5C, left) . Interestingly, we observed no difference between groups in response to administration of sodium nitroprusside ( Figure 5C , right), indicating that endothelium-independent vascular relaxation in Tie2-Angptl2 Tg mice was not impaired. Western analysis showed decreased phosphorylation of endothelial NO synthase (eNOS) in vessels from Tie2-Angptl2 Tg compared with wild-type control mice ( Figure 5D and 5E). However, there were no differences in serum levels of cholesterol, triglycerides, and FFAs, or systolic blood pressure between the 2 groups ( Figure XVI in the online-only Data Supplement). Furthermore, there was no difference in glucose metabolism as estimated by a glucose tolerance test between the 2 groups (data not shown). Overall, these findings suggest that endothelial cell-derived Angptl2 promotes eNOS inactivation in endothelial cells, leading to endothelial dysfunction at stages of atherosclerosis preceding atherosclerotic plaque formation and independent of insulin resistance and dyslipidemia.
Endothelial Dysfunction Is Attenuated by Angptl2 Deficiency in High-Fat Diet-Induced Obese and Dyslipidemic Mice
Because a high-fat diet or obesity is a major risk factor for endothelial dysfunction, we asked whether endothelial dysfunction occurred in obese mice fed a high-fat diet compared with nonobese mice fed a normal chow. As anticipated, endothelium-dependent relaxation after acetylcholine administration was significantly impaired in the aorta of wild-type obese mice fed a high-fat diet compared with wild-type nonobese mice fed normal chow. However, there was no difference in endothelium-independent relaxation in response to sodium nitroprusside between the 2 groups ( Figure XVII in the onlineonly Data Supplement). We next asked whether endothelial cell Angptl2 expression would increase in obese mice fed a high-fat diet and, if so, whether it would promote endothelial dysfunction. We observed robust Angptl2 expression in endothelial cells of wild-type mice made obese through exposure to a highfat diet (Figure 6A, lower) , although those mice did not exhibit significant evidence of atheromatous plaques. In contrast, Angptl2 expression was minimal in endothelial cells from nonobese mice fed normal chow ( Figure 6A, upper) . Subsequently, we asked whether endothelial dysfunction was ameliorated in Angptl2 −/− obese mice fed a high-fat diet. Markedly, impaired endothelium-dependent relaxation in response to acetylcholine was observed in the aorta of wild-type obese mice fed a high-fat diet, whereas that impairment was significantly attenuated in the aorta of similarly fed Angptl2 −/− obese mice ( Figure 6B , left graph). In contrast, we observed no difference in endotheliumindependent relaxation in response to sodium nitroprusside between both groups ( Figure 6B, right graph) . However, we observed no significant difference in endothelium-dependent relaxation in response to acetylcholine and endothelium-independent relaxation in response to sodium nitroprusside between wild-type and Angptl2 −/− mice fed a normal chow diet ( Figure  XVIII in the online-only Data Supplement). Western blots for phosphorylated eNOS in aorta tissue indicated decreased eNOS activation in vessels from wild-type obese mice fed a high-fat diet, whereas those changes were attenuated in Angptl2 −/− obese mice fed a high-fat diet (Figure 6C and 6D) . We observed no difference in serum levels of total cholesterol, triglycerides, or FFAs or in systolic blood pressure between genotypes ( Figure  XIX in the online-only Data Supplement). Overall, these findings suggest that deficiency of endothelial cell-derived Angptl2 attenuates endothelial dysfunction in high-fat diet-induced obese mice by antagonizing eNOS inactivation, and that this effect is independent of dyslipidemia.
Angptl2 Expression in Endothelial Cell Is Increased by Thrombin-Activated Calcineurin/ Nuclear Factor of Activated T Cell Signaling
Thrombin activation in endothelial cell increases blood coagulation and inflammation, both risk factors for CHD events, 27 and thrombotic events such as stroke and myocardial infarction are significant causes of morbidity and mortality in the elderly. 28 Therefore, we performed a microarray analysis of human umbilical vein endothelial cells to identify factors whose expression might by altered by thrombin stimulation. Interestingly, Angptl2 was significantly increased after 18 hours of thrombin treatment ( Figure XX activates calcineurin/nuclear factor of activated T cell signaling in endothelial cells. 29 In addition, Angptl2 expression in cancer cells increases after activation of calcineurin/nuclear factor of activated T cell signaling. 15 RT-PCR analysis revealed that expression of Angptl2 increased after stimulation of HCAECs with recombinant human thrombin; thrombin-increased Angptl2 expression was inhibited by adding the calcineurin inhibitor cyclosporine A ( Figure XXI in the online-only Data Supplement). Taken together, we found that thrombin induces Angptl2 expression in endothelial cells through activating calcineurin/nuclear factor of activated T cell signaling.
Elevated Circulating Angptl2 Levels Reflect Arteriosclerosis Development in Older Subjects Without a History of CVD
Finally, we assessed a potential contribution of Angptl2 to atherosclerosis in humans. To do so, we analyzed cohort of 417 seniors between 85 and 99 years with no history of CVD from 1 community in Tokyo ( Table III in the online-only Data Supplement). We observed that serum Angptl2 levels were correlated positively with vascular inflammatory status, based on estimation of circulating levels of vascular inflammatory markers ( Table IV in the online-only Data Supplement). Levels of other inflammatory markers, such as C-reactive protein, TNF-α, and IL-6, were also correlated positively with vascular inflammatory status ( Table IV in the online-only Data Supplement). We then asked whether serum Angptl2 levels were associated with intimal-medial thickness and arterial plaques in 359 of the 417 cited seniors who had received carotid artery ultrasound analysis because both intimal-medial thickness and presence of plaque in the carotid artery are well-characterized CHD risk factors. 30 Interestingly, serum Angptl2 levels were correlated positively with both intimal-medial thickness and the presence of plaque, whereas C-reactive protein, TNF-α, and IL-6 levels were not ( Table  V in the online-only Data Supplement). Furthermore, that association was maintained even after adjustment for traditional CHD risk factors and other mediators (Table VI in the online-only Data Supplement). These findings indicate overall that circulating Angptl2 concentrations reflect arteriosclerosis and suggest that high Angptl2 levels could predispose even subjects with no history of CVD to a future CHD event.
Discussion
In this study, we used mouse models and in vitro cultured cells to demonstrate that endothelial cell-derived Angptl2 activates NF-κB-dependent proinflammatory signaling in endothelial cells in an autocrine/paracrine manner and increases the number of infiltrated macrophages into atheromatous plaques. We propose that these events lead to chronic inflammation in the vessel wall and atherosclerosis progression. We also show that Angptl2-dependent NF-κB activation in endothelial cells promotes eNOS inactivation and endothelial dysfunction at subsequent stages of atherosclerotic plaque formation. We also report that Angptl2 is abundantly expressed in endothelial cells and infiltrated macrophages in atheromatous plaques and in endothelial cells in nonatheromatous plaque lesions from patients with CHD, and that elevated circulating Angptl2 concentrations reflect arteriosclerosis in a cohort of Japanese individuals with no history of CVD, suggesting that Angptl2 contributes to atherosclerosis development in humans.
As wild-type mice age, they show increased circulating Angptl2 concentrations without any significant atherosclerosis, although to a lesser extent than do ApoE −/− mice (Figure 1 ). We also observed that circulating Angptl2 levels increased with age in the general Japanese population ( Figure XXII in the online-only Data Supplement). Therefore, we investigated potential mechanisms underlying these increases. We observed that in humans, circulating levels of a thrombin-antithrombin complex significantly increase with age even in healthy volunteers with no CVD history ( Figure XXIII in the online-only Data Supplement). Here, we also found that thrombin stimulates Angptl2 expression in human endothelial cells by activating calcineurin/nuclear factor of activated T cell signaling. Thus, we hypothesize that increased circulating thrombin stimulates Angptl2 secretion by endothelial cells in the older population. Other mechanisms not directly related to aging may also contribute to Angptl2 upregulation. For example, endothelial cells derived from segments of mammary arteries from smokers with CHD reportedly express higher levels of Angptl2 mRNA than do those from tissues of either nonsmokers or former smokers by ≈3-fold. 31 Tie2-Angptl2 Tg mice showed significant endothelial dysfunction compared with respective wild-type controls, and the difference in Angptl2 mRNA levels in endothelial cells between Tg and wild-type mice was also 2-to 3-fold. Because smoking is associated closely with vascular inflammation and increased risk of atherosclerosis, 24, 32 increased Angptl2 expression in endothelial cells by smoking may partially contribute to vascular inflammation, endothelial dysfunction, and atherosclerosis development.
Although we found that Angptl2 is abundantly expressed in endothelial cells and infiltrated macrophages in atheromatous plaques, we focused on the pathophysiological role of endothelial cell-derived Angptl2 in atherosclerosis development. We found that endothelial cell-derived Angptl2 accelerates atherosclerosis progression through activating a proinflammatory cascade in endothelial cells and increasing macrophage infiltration ( Figure XXIV in online-only Data Supplement). Vascular inflammation emerges from the interplay of different cell types in vascular tissue structures, including endothelial cells, smooth muscle cells, and perivascular adipocytes as resident cells and macrophages as infiltrating cells. Relevant to this, we have reported that perivascular adipose tissue-derived Angptl2 accelerates neointimal hyperplasia after endovascular injury in mice 33 and that macrophage-derived Angptl2 functions in abdominal aortic aneurysms in mice. 34 Taken together with results from this study, we conclude that endothelial cells, infiltrated macrophages, and perivascular adipose tissue cooperate to produce Angptl2, which in turn accelerates endothelial cell inflammation and macrophage infiltration, leading to atherosclerosis development. RT-PCR analysis of isolated macrophages from ApoE −/− /Angptl2 −/− mice and ApoE −/− littermates suggested that Angptl2 deficiency in vivo may partially shift the population of macrophages from an inflammatory to an anti-inflammatory state. Conversely, our previous in vitro culture experiments using macrophages isolated from Angptl2 −/− mice showed that Angptl2 shifts the population of macrophages from an antiinflammatory to an inflammatory state. 34 Taken together with these findings, we demonstrate that Angptl2 could serve as a target to decrease atherosclerosis, although further analysis is required to determine whether Angptl2 alters macrophage inflammatory phenotypes in human disease.
Because Tie2-Angptl2 Tg mice show significantly greater Angptl2 expression in hematopoietic stem cells than do the wild-type mice, we asked whether the number of circulating leukocytes changes in ApoE −/− /Tie2-Angptl2 Tg mice, an outcome that could contribute to atherosclerotic phenotypes. However, we observed no difference in peripheral circulating leukocyte numbers between ApoE −/− /Tie2-Angptl2 Tg mice and ApoE −/− littermates ( Figure XI in the online-only Data Supplement). Thus, there is little possibility that differences in numbers of circulating leukocytes numbers underlie atherosclerotic phenotypes seen in ApoE −/− /Tie2-Angptl2 Tg mice.
Increased insulin sensitivity because of systemic Angptl2 deficiency may contribute, in part, to decreased atherosclerosis progression seen in ApoE −/− /Angptl2 −/− mice. Although this study demonstrates that deficiency of endothelial cell-derived Angptl2 attenuates endothelial dysfunction in high-fat diet-induced obese mice by antagonizing eNOS inactivation, an effect independent of dyslipidemia, we previously reported that insulin resistance, which also causes endothelial dysfunction, was attenuated in Angptl2 −/− obese mice. 10 Therefore, decreased insulin resistance might also contribute partially to decreased endothelial dysfunction in Angptl2 −/− obese mice. Overall, we conclude that decreased levels of systemic Angptl2 may decrease atherosclerosis and endothelial dysfunction by increasing insulin sensitivity in normal glucose metabolic conditions and decreasing insulin resistance under glucose metabolic dysfunction.
ApoE −/− /Tie2-Angptl2 Tg mice exhibited accelerated atherosclerosis development but showed no difference in levels of serum cholesterol, triglycerides, and FFAs compared with littermate ApoE −/− mice. In addition, ApoE −/− /Angptl2 −/− double-knockout mice showed attenuated atherosclerosis development relative to ApoE −/− /Angptl2 +/+ single-knockout littermates, but no significant differences in serum cholesterol, triglycerides, and FFAs. These findings demonstrate that Angptl2 accelerates atherosclerosis progression without influencing circulating cholesterol levels. Angptl3 and Angptl4, which are other Angptl family members, accelerate atherosclerosis development by exacerbating dyslipidemia, 35 indicating that Angptl activities likely differ. This observation is consistent with our previous clinical reports showing no correlation between circulating Angptl2 concentrations and total cholesterol levels in the general Japanese population 36 or that there is no correlation between changes in circulating Angptl2 concentrations and changes in low-density lipoprotein-cholesterol levels in overweight Japanese men after lifestyle intervention. 37 During preparation of our article, others reported that Angptl2 contributes to atherosclerosis development. 38 That group reported that chronic infusion of Angptl2 into preatherosclerotic dyslipidemic (LDLr −/− ; hApoB100 +/+ ) mice accelerates atherosclerosis development through vascular inflammation and increased levels of circulating cholesterol. At present, we cannot explain these discrepancies with our findings relevant to Angptl2 function and circulating cholesterol levels.
Male and female humans show some differences in pathophysiological risk of atherosclerosis. Thus, we used only male mice in this study, although further studies are required to investigate a potential Angptl2 contribution to atherosclerosis development in female animals. Also, to create obese wild-type mice, we used a high-fat diet-32, which contains a high percentage of fat-derived calories relative to a standard Western diet. Thus, in the future, it will be important to repeat our analysis using standard Western and control diets to confirm the effect of Angptl2 on endothelial dysfunction.
In summary, we provide the first evidence that endothelial cell-derived Angptl2 accelerates vascular inflammation by activating an NF-κB-dependent proinflammatory cascade in endothelial cells and increasing infiltrated macrophages into atherosclerotic lesions, leading to endothelial dysfunction and progression of atheromatous plaque formation and instability in mice. In addition, systemic Angptl2 deficiency slows atherosclerosis progression and decreases plaque instability in ApoE −/− mice and attenuates endothelial dysfunction in wild-type mice made obese by a high-fat diet. These effects are attributable to decreased vascular inflammation and partially to increased insulin sensitivity. Our work has potential clinical relevance as it suggests that circulating Angptl2 concentrations may reflect arteriosclerosis in humans. Further clinical investigation is needed to determine whether reduction of circulating Angptl2 levels would constitute an effective treatment for patients with CVD or whether Angptl2 is a potential target for developing prevention and treatment strategies for CVD.
